Semaglutide Research
Product image coming soon
Semaglutide: GLP-1 Receptor Agonist Research Profile
Semaglutide is a synthetic long-acting GLP-1 receptor agonist studied in laboratory settings for its role in incretin signalling, glucose-dependent insulin secretion, and appetite regulation research. It was developed as an improved analogue of native GLP-1 with dramatically extended half-life achieved through fatty acid conjugation enabling albumin binding.
Semaglutide: GLP-1R Agonist Mechanism
Chemical and Molecular Data
| Property | Value |
|---|---|
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.58 g/mol |
| CAS number | 910463-68-2 |
| Drug class | GLP-1 receptor agonist |
| Purity | greater than or equal to 98% as verified by HPLC |
| Form | Lyophilised powder |
| Storage | -20 degrees C, protected from light and moisture |
| Reconstitution | Bacteriostatic water recommended |
Semaglutide: GLP-1R Agonist Mechanism
Structural Design and Extended Half-Life
Semaglutide is based on native GLP-1(7-37) with three key modifications. First, Aib (alpha-aminoisobutyric acid) replaces Ala at position 8, preventing DPP-IV cleavage — the primary route of GLP-1 degradation in plasma. Second, Arg34 replaces Lys34, removing an unwanted fatty acid attachment site. Third, a C18 fatty diacid chain is attached via a linker to Lys26, enabling high-affinity non-covalent binding to serum albumin.
This albumin binding extends the effective plasma half-life to approximately 7 days in humans, enabling once-weekly administration in clinical settings and making it a useful tool for studying sustained GLP-1R agonism versus the pulsatile stimulation of shorter-acting analogues like exendin-4.
GLP-1 Receptor Pharmacology
The GLP-1 receptor (GLP-1R) is a class B GPCR coupled to Gs, activating adenylyl cyclase to raise intracellular cAMP and activate protein kinase A (PKA). GLP-1R is expressed on pancreatic beta cells, hypothalamic neurons, gastric tissue, and the vagal nerve, among other sites.
Laboratory research has examined semaglutide in the context of:
Glucose-dependent insulin secretion. In pancreatic beta cell models, GLP-1R activation enhances insulin gene transcription and exocytosis in a glucose-dependent manner — this glucose-dependency is a key feature studied in comparison with sulphonylureas, which stimulate insulin release independently of glucose.
Appetite regulation research. Hypothalamic GLP-1R expression and its role in reducing food intake has been examined in rodent models. Research has investigated the role of vagal nerve GLP-1R signalling in satiety signalling.
Beta cell biology. Research has examined GLP-1R agonism in models of beta cell proliferation, survival, and protection from apoptosis under glucotoxic and lipotoxic conditions.
Comparison with Tirzepatide and Retatrutide
Semaglutide is a GLP-1R monoagonist, making it a useful reference compound in comparative pharmacology studies alongside Tirzepatide (dual GLP-1R/GIPR agonist) and Retatrutide (triple GLP-1R/GIPR/GCGR agonist). Comparing these three compounds in receptor binding and functional assays allows researchers to dissect the incremental pharmacological contributions of GIPR and GCGR co-agonism.
Research Applications
Semaglutide is used as a tool compound in GLP-1R binding and functional assays, beta cell biology research, hypothalamic appetite regulation studies, incretin hormone pharmacology, and as a reference compound in comparative incretin research.
GLP-1R Agonist Comparison
| Compound | Type | GLP-1R | GIPR | GCGR | Half-life | Route |
|---|---|---|---|---|---|---|
| Exendin-4 | Peptide | Full agonist | — | — | ~2.4 hr | — |
| Liraglutide | Peptide + C16 FA | Full agonist | — | — | ~13 hr | SC |
| Semaglutide | Peptide + C18 FA | Full agonist | — | — | ~7 days | SC/oral |
| Tirzepatide | Peptide + C20 FA | Partial/biased | Full agonist | — | ~5 days | SC |
| Retatrutide | Peptide + FA | Agonist | Agonist | Agonist | ~6 days | SC |
Frequently Asked Questions
What is the Aib modification in Semaglutide and why is it important?
Alpha-aminoisobutyric acid (Aib) is a non-natural amino acid with two methyl groups on the alpha carbon, making it resistant to cleavage by dipeptidyl peptidase IV (DPP-IV). Native GLP-1 is inactivated within minutes by DPP-IV at the Ala-Glu bond between positions 2 and 3. By substituting Aib for Ala at position 8, Semaglutide resists this cleavage entirely. This single substitution is responsible for the transition from the very short half-life of native GLP-1 (approximately 2 minutes) to the extended half-life that the fatty acid modification then extends to approximately 7 days.
How does Semaglutide's GLP-1R bias differ from Tirzepatide's?
Semaglutide is a balanced full agonist at GLP-1R — it activates both G-protein (Gs/cAMP) and beta-arrestin pathways with approximately equal potency. Tirzepatide, despite also binding GLP-1R, demonstrates biased agonism — it preferentially activates G-protein signalling over beta-arrestin recruitment at GLP-1R. This pharmacological bias is thought to reduce receptor internalisation and alter the pattern of GLP-1R desensitisation, potentially contributing to differences in their downstream biological effects in research models.
What is the significance of Arg34 in the Semaglutide sequence?
Native GLP-1(7-37) has a lysine at position 34 (Lys34). In the development of Semaglutide, Lys34 was substituted with Arg34 to eliminate an undesired fatty acid attachment site. The C18 fatty diacid chain needed to be attached specifically to Lys26, and if Lys34 were present, a proportion of the synthetic peptide would have fatty acid attached at the wrong position. The Arg34 substitution ensures site-specific fatty acid conjugation at Lys26 during synthesis.
Published Research References
For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.
Related research peptides: Tirzepatide | Retatrutide | Tesamorelin